Le Lézard
Classified in: Covid-19 virus
Subjects: Photo/Multimedia, Product/Service, Corporate Social Responsibility

Nexus Pharmaceuticals Makes Key Investment to Help COVID-19 Vaccine Effort


Nexus Pharmaceuticals Inc., a US-based healthcare company and domestic manufacturer, today announced that they transported via a special air freight charter through DB Schenker 82 tons of vaccine filling equipment, including a vaccine filling machine and isolator from Bausch + Stroebel and Franz Ziel. Once the production line is operational, Nexus will have the capability to produce up to 30 million doses of vaccines per month.

"Nexus remains committed to helping our nation, as well as the global community, overcome the COVID-19 pandemic by utilizing our new state-of-the-art Wisconsin manufacturing facility," said Usman Ahmed, COO of Nexus Pharmaceuticals, Inc. "Since January, we have been engaged with the Biden administration and members of Congress to activate the Defense Production Act (DPA) so that pharmaceutical companies like Nexus can manufacture and distribute millions of doses of the COVID-19 vaccine. By investing in this new, specialized vaccine line filling equipment, Nexus is taking a proactive step to ensure that we are ready to answer the call and play a role in helping fight this deadly pandemic."

About Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals, Inc. is a US-based, woman-led, minority-owned healthcare company and certified diverse supplier, specializing in innovative processes to make difficult-to-manufacture specialty and generic injectables that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they're needed most. For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility and Live Cam, please visit https://www.nexuspharma.net/project-tomorrow/.


These press releases may also interest you

at 16:00
FACILITY TO SUPPORT SUSTAINABILITY OBJECTIVES OF EUROPEAN CONSUMER PACKAGED GOODS COMPANIESBREAKING GROUND OF NEW FACILITY TARGETED FOR 2023 WITH FACILITY STARTUP AND COMMISSIONING APPROXIMATELY 18 MONTHS LATERINFINITE LOOP™ MANUFACTURING MODEL...

at 11:34
A winter storm continues to move through the Carolinas today, cutting power to 67,000 Duke Energy customers so far, with more power outages likely to occur later today and into early Monday....

at 06:30
As part of Georgia Governor Brian Kemp's initiative to increase the availability and access to efficient COVID-19 PCR testing, Viral Solutions has been chosen by the Georgia Department of Public Health (GaDPH) to spearhead an effort to rapidly open...

15 jan 2022
Effective immediately, UNC Health hospitals will no longer administer COVID tests to the general public who are not experiencing symptoms in their emergency departments (EDs). With the impact of the Omicron variant, emergency departments at hospitals...

15 jan 2022
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Talis Biomedical Corporation common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in...

15 jan 2022
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Talis Biomedical Corporation ("Talis") . The action charges Talis with violations of the federal securities laws,...



News published on 14 april 2021 at 17:20 and distributed by: